Abstract
Cyclin-dependent kinases 4 and 6 (Cdk4/6) are important components of cell cycle activation and control in early G(1) phase. Both enzymes and their regulators, e.g., cyclins, play critical roles in embryogenesis, homeostasis, and cancerogenesis. Cdk4/6 are attractive targets for cancer treatment. Recently, numerous selective small molecule inhibitors of Cdk4/6 have been developed. The potential of Cdk4/6 inhibitors, particularly, pyrido[2,3-d]pyrimidine derivatives, as both anti-cancer drugs and 124I- and 18F-radiolabeled tracers for cancer imaging using positron emission tomography is discussed.
MeSH terms
-
Animals
-
Antineoplastic Agents / chemistry*
-
Antineoplastic Agents / therapeutic use
-
Cyclin-Dependent Kinase 4 / antagonists & inhibitors*
-
Cyclin-Dependent Kinase 4 / metabolism
-
Cyclin-Dependent Kinase 6 / antagonists & inhibitors*
-
Cyclin-Dependent Kinase 6 / metabolism
-
Mice
-
Neoplasms / diagnosis
-
Neoplasms / drug therapy*
-
Positron-Emission Tomography
-
Protein Kinase Inhibitors / chemistry*
-
Protein Kinase Inhibitors / therapeutic use
-
Pyrimidines / chemistry
-
Pyrimidines / therapeutic use
Substances
-
Antineoplastic Agents
-
Protein Kinase Inhibitors
-
Pyrimidines
-
Cyclin-Dependent Kinase 4
-
Cyclin-Dependent Kinase 6